New-Onset Heart Failure Due to Heart Muscle Disease in Childhood: A Prospective Study in the United Kingdom and Ireland

Background— We undertook the first prospective, national, multicenter study to describe the incidence and outcome of heart muscle disease–induced heart failure in children. Methods and Results— Data were collected on patients admitted to a hospital through 2003 with a first episode of heart failure in the absence of congenital heart disease. All 17 pediatric cardiac centers in the United Kingdom and Ireland participated. Follow-up data were obtained to a minimum of 1 year. The incidence was 0.87/100 000 population <16 years (n=104; 53 girls; 95% confidence interval 0.71 to 1.05 per 100 000). Median age at presentation was 1 year, with 82% in New York Heart Association class III to IV. Causes of heart failure included dilated cardiomyopathy (50 idiopathic, 8 familial), probable myocarditis (23), occult arrhythmia (7), anthracycline toxicity (5), metabolic disease (4), left ventricular noncompaction (3), and other (4). Overall 1-year survival was 82%, and event (death or transplantation)-free survival was 66%. Regression analysis showed older age and reduced systolic function on admission echocardiogram increased the event risk. Only 8% of event-free survivors (n=69) remained in New York Heart Association class III to IV, but 35 required readmission during the study period, and all but 8 remained on medication. Conclusions— This first national prospective study of new-onset heart failure in children has shown an incidence of 0.87/100 000. Multivariable analysis of survival data indicates a better outcome for younger children and for those with better systolic function at presentation, but overall, one third of children die or require transplantation within 1 year of presentation.

[1]  P. Clarkson,et al.  Efficacy and dosage of enalapril in congenital and acquired heart disease. , 1994, Archives of disease in childhood.

[2]  C. Bearzi,et al.  Concise Review: Stem Cells, Myocardial Regeneration, and Methodological Artifacts , 2007, Stem cells.

[3]  A. Rahmel,et al.  Registry of the International Society for Heart and Lung Transplantation: Twelfth Official Pediatric Heart Transplantation Report-2009. , 2009, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  E. Trulock,et al.  Registry of the International Society for Heart and Lung Transplantation: ninth official pediatric heart transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[5]  Leslie Hamilton,et al.  The waiting game: bridging to paediatric heart transplantation. , 2003, Lancet.

[6]  J. Matthews,et al.  Prognostic features of children with idiopathic dilated cardiomyopathy. , 1991, The American journal of cardiology.

[7]  W. Grimm,et al.  Noninvasive Arrhythmia Risk Stratification in Idiopathic Dilated Cardiomyopathy: Results of the Marburg Cardiomyopathy Study , 2003, Circulation.

[8]  O. Ruuskanen,et al.  Idiopathic Dilated Cardiomyopathy in Children: Prognostic Indicators and Outcome , 1998, Pediatrics.

[9]  E John Orav,et al.  The incidence of pediatric cardiomyopathy in two regions of the United States. , 2003, The New England journal of medicine.

[10]  R. Friedman,et al.  Clinical course of idiopathic dilated cardiomyopathy in children. , 1991, Journal of the American College of Cardiology.

[11]  S. Nouri,et al.  Clinical profile of congestive cardiomyopathy in children. , 1990, Journal of the American College of Cardiology.

[12]  L. Pérez Díaz,et al.  [Dilated cardiomyopathy in infants and children]. , 1994, Revista espanola de cardiologia.

[13]  O. Simell,et al.  Epidemiology of idiopathic cardiomyopathies in children and adolescents. A nationwide study in Finland. , 1997, American journal of epidemiology.

[14]  John B Carlin,et al.  The epidemiology of childhood cardiomyopathy in Australia. , 2003, The New England journal of medicine.

[15]  M. Burch,et al.  Dilated cardiomyopathy in children: determinants of outcome. , 1994, British heart journal.

[16]  K. Baughman Diagnosis of myocarditis: death of Dallas criteria. , 2006, Circulation.

[17]  Marshall I Hertz,et al.  Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report--2006. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[18]  C. Canter,et al.  Carvedilol as therapy in pediatric heart failure: an initial multicenter experience. , 2001, The Journal of pediatrics.

[19]  A. Matsumori,et al.  Epidemiology of idiopathic cardiomyopathy in Japan: results from a nationwide survey , 2002, Heart.

[20]  O. Gómez-Marín,et al.  Carvedilol in children with cardiomyopathy: 3-year experience at a single institution. , 2004, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[21]  Michael Burch,et al.  Improved early outcome for end-stage dilated cardiomyopathy in children. , 2003, The Journal of thoracic and cardiovascular surgery.

[22]  Jared W. Magnani,et al.  Myocarditis: Current Trends in Diagnosis and Treatment , 2006, Circulation.

[23]  A. Lewis,et al.  Outcome of infants and children with dilated cardiomyopathy. , 1991, The American journal of cardiology.

[24]  S. Colan,et al.  Improved outcomes of pediatric dilated cardiomyopathy with utilization of heart transplantation. , 2004, Journal of the American College of Cardiology.

[25]  Paul Aurora,et al.  Registry of the International Society for Heart and Lung Transplantation: tenth official pediatric heart transplantation report--2007. , 2007, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[26]  S. Nouri,et al.  Clinical profile of conjestive cardiomyopathy in children , 1990 .

[27]  R. Spicer Carvedilol--a new dimension in pediatric heart failure therapy. , 2001, The Journal of pediatrics.